Analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a report issued on Monday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of NYSE NAVB opened at $0.00 on Monday. The company has a market cap of $20,016.00, a PE ratio of 0.00 and a beta of 0.76. The business has a 50-day simple moving average of $0.03 and a two-hundred day simple moving average of $0.04. Navidea Biopharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.15.
About Navidea Biopharmaceuticals
See Also
- Five stocks we like better than Navidea Biopharmaceuticals
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Chipotle Mexican Grill Stock Split: Where Does it Go From Here?
- How to Calculate Return on Investment (ROI)
- Arm Holdings and Micron: Top 2 AI Stocks to Buy and Hold
- The How And Why of Investing in Oil Stocks
- Best Buy Stock May Be Best Bought Before the Holiday Season
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.